Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-Current Deffered Revenue (2016 - 2017)

Historic Non-Current Deffered Revenue for Aytu Biopharma (AYTU) over the last 3 years, with Q3 2017 value amounting to $3.0 billion.

  • Aytu Biopharma's Non-Current Deffered Revenue rose 4647550030.98% to $3.0 billion in Q3 2017 from the same period last year, while for Sep 2017 it was $3.0 billion, marking a year-over-year increase of 4647550030.98%. This contributed to the annual value of $1451.0 for FY2017, which is 8233.72% down from last year.
  • According to the latest figures from Q3 2017, Aytu Biopharma's Non-Current Deffered Revenue is $3.0 billion, which was up 4647550030.98% from $1451.0 recorded in Q2 2017.
  • Over the past 5 years, Aytu Biopharma's Non-Current Deffered Revenue peaked at $5.0 billion during Q4 2016, and registered a low of $1451.0 during Q2 2017.
  • Its 3-year average for Non-Current Deffered Revenue is $800.2 million, with a median of $372321.5 in 2015.
  • Within the past 5 years, the most significant YoY rise in Aytu Biopharma's Non-Current Deffered Revenue was 4647550030.98% (2017), while the steepest drop was 9913.75% (2017).
  • Aytu Biopharma's Non-Current Deffered Revenue (Quarter) stood at $383036.0 in 2015, then soared by 1305260.33% to $5.0 billion in 2016, then tumbled by 40.0% to $3.0 billion in 2017.
  • Its Non-Current Deffered Revenue stands at $3.0 billion for Q3 2017, versus $1451.0 for Q2 2017 and $3119.0 for Q1 2017.